Topoisomerase mutations that are associated with high-level resistance to earlier fluoroquinolones in staphylococcus aureus have less effect on the antibacterial activity of besifloxacin

Chemotherapy

Volumn 57, Issue 5, 2011, Pages 363-371

  Sanfilippo, Christine M ^a,b   Hesje, Christine K ^a   Haas, Wolfgang ^a   Morris, Timothy W ^a  

^a BAUSCH AND LOMB   (United States)

^b NONE   (United States)

Author keywords

Besifloxacin; Fluoroquinolones; Staphylococcus aureus; Topoisomerase mutations

Indexed keywords

BESIFLOXACIN; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; GATIFLOXACIN; GENOMIC DNA; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; MINIMUM INHIBITORY CONCENTRATION; MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

EID: 80053914437     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000330858     Document Type: Article

References (30)

1. Karpecki P, DePaolis M, Hunter JA, White EM, Rigel L, Brunner LS, Usner DW, Paterno MR, Comstock TL: Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: a multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study. Clin Ther 2009; 31: 514-52 6.
2. McDonald MB, Protzko EE, Brunner LS, Morris TW, Haas W, Paterno MR, Comstock TL, Usner DW: Efficacy and safety of besi-floxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis. Ophthalmology 2009; 116: 1615-1623.
3. Tepedino ME, Heller WH, Usner DW, Brun-ner LS, Morris TW, Haas W, Paterno MR, Comstock T: Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr Med Res Opin 2009; 25:1159-1169.
4. Haas W, Pillar CP, Zurenko GE, Lee JC, Brunner LS, Morris TW: Besif loxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. Antimicrob Agents Chemother 2009; 53: 3552-3560.
5. Hooper DC: Mechanisms of f luoroquinolone resistance. Drug Resist Updat 1999; 2:38-55.
6. Ferrero L, Cameron B, Manse B, Lagneaux D, Crouzet J, Famechon A, Blanche F: Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol Microbiol 1994; 13: 641-653. (Pubitemid 24266200)
7. German N, Wei P, Kaatz GW, Kerns RJ: Synthesis and evaluation of fluoroquinolone derivatives as substrate-based inhibitors of bacterial efflux pumps. Eur J Med Chem 2008; 43:2453-2463.
8. Neyfakh AA, Borsch CM, Kaatz GW: Fluo-roquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporter. Antimicrob Agents Chemother 1993; 37: 128-129. (Pubitemid 23019184)
9. McAleese F, Petersen P, Ruzin A, Dunman PM, Murphy E, Projan SJ, Bradford PA: A novel M AT E fa mi ly ef f lu x pu mp c ont r ibutes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to ti-gecycline. Antimicrob Agents Chemother 2005; 49:1865-1871. (Pubitemid 40631601)
10. Drl ica K, Hooper DC: Mechanisms of quino-lone action; in Hooper DC, Rubinstein E (eds): Quinolone Antimicrobial Agents. Washington, DC, ASM Press, 2003, pp 19-40.
11. Hooper DC: Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin Infect Dis 2001; 328(suppl 1):S9-S15. (Pubitemid 32506740)
12. Blondeau JM: Fluoroquinolones: mechanism of action, classification, and development of resistance. Surv Ophthalmol 2004; 49(suppl 2):S73-S78. (Pubitemid 38353038)
13. Hesje CK, Sanfilippo CM, Haas W, Morris TW: Molecular epidemiology of methicillin-resistant and methicillin-susceptible Staph-ylococcus aureus isolated from the eye. Curr Eye Res 2011; 36:94-102.
14. Cambau E, Matrat S, Pan XS, Roth Dit BR, Corbel C, Aubry A, Lascols C, Driot JY, Fisher LM: Target specificity of the new fluoro-quinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli. J Antimicrob Chemother 2009; 63:443-450.
15. Laponogov I, Sohi MK, Veselkov DA, Pan XS, Sawhney R, Thompson AW, McAuley KE, Fisher LM, Sanderson MR: Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases. Nat Struct Mol Biol 2009; 16:667-669.
16. Wohlkonig A, Chan PF, Fosberry AP, Homes P, Huang J, Kranz M, Leydon VR, Miles TJ, Pearson ND, Perera RL, Shillings AJ, Gwynn MN, Bax BD: Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance. Nat Struct Mol Biol 2010; 17:1152-1153.
17. Bax BD, Chan PF, Eggleston DS, Fosberry A, Gentry DR, Gorrec F, Giordano I, Hann MM, Hennessy A, Hibbs M, Huang J, Jones E, Jones J, Brown KK, Lewis CJ, May EW, Saunders MR, Singh O, Spitzfaden CE, Shen C, Shillings A, Theobald AJ, Wohlkonig A, Pearson ND, Gwynn MN: Type IIA topoi-somerase inhibition by a new class of antibacterial agents. Nature 2010; 466: 935-940.
18. Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement. CLSI document M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA, 2010.
19. Clinical and Laboratory Standards Institute: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobi-cally; Approved Standard, Eighth Edition. CLSI document M7-A8. Clinical and Laboratory Standards Institute, Wayne, PA, 2009.
20. Lu T, Zhao X, Li X, Drlica-Wagner A, Wang JY, Domagala J, Drlica K: Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegma-tis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus. Antimi-crob Agents Chemother 2001; 45:2703-2709. (Pubitemid 32906660)
21. Hooper DC: Fluoroquinolone resistance among Gram-positive cocci. Lancet Infect Dis 2002; 2: 53 0-53 8.
22. Tanaka M, Onodera Y, Uchida Y, Sato K: Quinolone resistance mutations in the GrlB protein of Staphylococcus aureus. Antimi-crob Agents Chemother 1998; 42:3044-3046. (Pubitemid 28501253)
23. Morosini MI, Loza E, del CR, Almaraz F, Baquero F, Canton R: Fluoroquinolone-re-sistant Streptococcus pneumoniae in Spain: activities of garenoxacin against clinical isolates including strains with altered topoi-somerases. Antimicrob Agents Chemother 2003; 47:2692-2695. (Pubitemid 36919484)
24. Hannachi-M'Zali F, Ambler JE, Taylor CF, Hawkey PM: Examination of single and multiple mutations involved in resistance to qui-nolones in Staphylococcus aureus by a combination of PCR and denaturing high-performance liquid chromatography (DHPLC). J Antimicrob Chemother 20 02; 50: 649-655. (Pubitemid 35331681)
25. Yoon EJ, Lee CY, Shim MJ, Min YH, Kwon AR, Lee J, Choi EC: Extended spectrum of quinolone resistance, even to a potential latter third-generation agent, as a result of a minimum of two GrlA and two GyrA alterations in quinolone-resistant Staphylococcus aureus. Chemot herapy 2010; 56: 153-157.
26. Shinabarger DL, Zurenko GE, Hesje C, San-filippo CM, Morris TW, Haas W: Evaluation of the effect of bacterial efflux pumps on the antibacterial activity of the novel fluoroqui-nolone besif loxacin. J Chemother 2011; 23: 80-86.
27. Yoshida H, Bogaki M, Nakamura M, Ya-manaka LM, Nakamura S: Quinolone resistance-determining region in the DNA gy-rase gyrB gene of Escherichia coli. Antimi-crob Agents Chemother 1991; 35: 1647-1650.
28. Heddle J, Maxwell A: Quinolone-binding pocket of DNA gyrase: role of GyrB. Antimi-crob Agents Chemother 2002; 46: 18 0 5-1815. (Pubitemid 34535201)
29. Noble CG, Maxwell A: The role of GyrB in the DNA cleavage-religation reaction of DNA gyrase: a proposed two metal-ion mechanism. J Mol Biol 2002; 318:361-371. (Pubitemid 34734831)
30. Seo MR, Park YS, Pai H: Characteristics of plasmid-mediated quinolone resistance genes in extended-spectrum cephalosporin-resistant isolates of Klebsiella pneumoniae and Escherichia coli in Korea. Chemotherapy 2010; 56: 46-53.